Table 5.
Prevalence of circulating filarial antigenaemia (CFA) by age group before and after mass drug administration (MDA)
| No. CFA positive/No. examined (% CFA positive) | |||||
| Age group (years) | 2002 (Pre-MDA) | 95% CI (%) | 2009 (Post MDA4) | 95% CI (%) | % Decrease |
| < 11 | 72/364 (19.8) | 15.7 - 23.9 | 3/217 (1.4) | 0.0 - 3.0 | 92.9 |
| 11 - 20 | 131/423 (31.0) | 26.6 - 35.4 | 20/396 (5.1) | 2.9 - 7.3 | 83.5 |
| 21 - 30 | 82/229 (35.8) | 29.6 - 42.0 | 19/106 (17.9) | 10.6 - 25.2 | 50.0 |
| 31 - 40 | 72/151 (47.7) | 39.7 - 55.7 | 24/125 (19.2) | 12.3 - 26.1 | 59.7 |
| 41 - 50 | 63/138 (45.7) | 37.4 - 54.0 | 20/105 (19.0) | 11.5 - 26.5 | 58.4 |
| > 50 | 81/142 (57.0) | 48.9 - 65.1 | 29/109 (26.6) | 18.3 - 34.9 | 53.3 |
| All | 501/1447 (34.6) | 32.1 - 37.1 | 115/1058 (10.8)* | 8.9 - 12.7 | 68.8 |
*excluding 38 individuals who had indeterminate results in 2009